HIV/HCV coinfected
people who take sofosbuvir/ledipasvir (Harvoni)
to treat hepatitis C along with boosted protease inhibitor antiretroviral
regimens may experience changes in drugs levels, but these are mostly not
considered clinically relevant, according to a drug-drug interaction study
presented at the 2015 Conference on Retroviruses and Opportunistic Infections
(CROI) last month in Seattle. However, data on the safety and efficacy of
combining sofosbuvir/ledipasvir with boosted protease inhibitors during
treatment are lacking, and increased tenofovir exposure may be a concern.

The advent of
interferon-free direct-acting antiviral regimens has brought about a revolution
in treatment for chronic hepatitis C virus (HCV) infection, including for
patients who have traditionally been considered 'difficult to treat', such as
those with HIV/HCV coinfection. Clinical trials have seen cure
rates for coinfected people equal to those for patients with HCV alone, and current
treatment guidelines and product labels indicate that HIV-positive patients can
be treated with the same recommended regimens as HIV-negative ones, taking into
account potential interactions with antiretroviral therapy (ART).